19-459 - S1400F: A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
Status: openS1400F: Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Treatment for stage IV lung cancer that has come back
Description
This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread
Sponsors
This trial is sponsored by National Cancer Institute (NCI).Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Sachin Pai]()
View ProfileSachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
Sub Investigators
This link will open in a new tab or window.